Integral Diagnostics Limited

ASX:IDX

Integral Diagnostics Limited

ASX:IDX
TradeAdd trade order Follow Unfollow Set Price Alert
$2.45 (-0.8%)
Last close price
#340
Rank
2
Held by
6
Followers
TradeAdd trade order Follow Unfollow Set Price Alert
Reports (3) My Report Forum Investors
Top member reports
Consensus
No meetings
Consensus community valuation
XXXXXX
Average Intrinsic Value
XXXXXX
Undervalued by
The consensus valuation is for members only and has been removed from this chart. Click for membership options.
Become a member
Contributing Members
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
Become a member
Valuation of $2.73
spacetimetrave
Added 5 months ago

6 months after aquisition + new FY reg changes as a benefit to the business model

Read More
#H1FY21 Results 22/2/21
stale
mmff
Added 5 years ago
View author's company report

The 1H21 results reflect solid organic growth, a full six-month contribution from Imaging Queensland, a fourmonth contribution from Ascot Radiology and the net impacts of COVID-19 including the receipt of JobKeeper that enabled the retention and support of our highly skilled workforce.

Group Summary

  •  Statutory NPAT of $19.9m after customer contract amortisation, transaction and other costs of $3.3m delivering an Operating NPAT of $23.2m
  •  Operating revenue of $170.7m
  •  Operating EBITDA $52.0m (30.5% margin)
  •  Operating EPS of 11.6 cents on operating NPAT of $23.2m
  •  Free cash flow of $42.7m with Net Debt of $137.3m
  •  Interim dividend (fully franked) of 5.5 cents per share payable on 6th April 2021

All key financial measures include the application of AASB 161.

View Attachment

Read More
Valuation of $4.75
stale
Jimmy
Added 6 years ago
BROKER COMMENTARY: BROKER initiated coverage in December with a positive view and this has not changed post release of what is being described as a "solid" performance in H1. Strong long term growth potential remains on the agenda, in the analysts' view. Acquisitions remain part of the strategy, with the analysts noting recent acquisitions are still being integrated. Organic growth should be strong. on their assessment. Target price rises to $4.90 from $4.30. Buy rating retained. The H1 decline in EBITDA margin is expected to reverse in H2. Indexation of government payments and further investments made add to the investment appeal for Citi.
Read More